{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:47:21Z","timestamp":1794710841488,"version":"4.9.1"},"reference-count":48,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2434,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1111\/j.1742-1241.2008.01934.x","type":"journal-article","created":{"date-parts":[[2008,11,28]],"date-time":"2008-11-28T15:09:52Z","timestamp":1227884992000},"page":"151-159","source":"Crossref","is-referenced-by-count":30,"title":["Does nicotinic acid (niacin) lower blood pressure?"],"prefix":"10.1155","volume":"63","author":[{"given":"H. E.","family":"Bays","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","reference":[{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch Biochem"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB2","first-page":"108","article-title":"Lipid-altering efficacy and tolerability profile of extended release niacin\/laropiprant in patients with primary hypercholesterolemia or mixed hyperlipidemia (abstract)","volume":"28","author":"Maccubbin","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB3","volume-title":"Blood Pressure-Lowering Effect of ER Niacin and ER Niacin\/Laropiprant in Dyslipidemic Patients","author":"Bays","year":"2008"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB4","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/01.CIR.83.2.438","article-title":"Effects of colestipol-niacin therapy on human femoral atherosclerosis","volume":"83","author":"Blankenhorn","year":"1991","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/01.CIR.88.1.20","article-title":"Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound","volume":"88","author":"Blankenhorn","year":"1993","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB7","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/0003-4819-119-10-199311150-00002","article-title":"Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS)","volume":"119","author":"Blankenhorn","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB9","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB10","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjcard.2004.09.013","article-title":"Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)","volume":"95","author":"Canner","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjcard.2005.08.070","article-title":"Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)","volume":"97","author":"Canner","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB14","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1001\/jama.1990.03450230049028","article-title":"Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up","volume":"264","author":"Cashin-Hemphill","year":"1990","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB15","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB16","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1161\/01.STR.24.12.1779","article-title":"One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol\/niacin therapy","volume":"24","author":"Mack","year":"1993","journal-title":"Stroke"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB17","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4065\/83.4.470","article-title":"Effects of niacin on glucose control in patients with dyslipidemia","volume":"83","author":"Goldberg","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MOL.0b013e3282364add","article-title":"Niacin in cardiovascular prevention: mechanisms, efficacy, and safety","volume":"18","author":"Guyton","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB21","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-2891-4-3","article-title":"The treatment of migraines and tension-type headaches with intravenous and oral niacin (nicotinic acid): systematic review of the literature","volume":"4","author":"Prousky","year":"2005","journal-title":"Nutr J"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB23","author":"Abbott Laboratories","year":"2007"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB24","author":"Abbott Laboratories","year":"2007"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0895-7061(02)03196-5","article-title":"Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects","volume":"16","author":"Gadegbeku","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.jhh.1001099","article-title":"Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects","volume":"14","author":"Kelly","year":"2000","journal-title":"J Hum Hypertens"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000169001","article-title":"Arterial compliance in hypertension and diabetes mellitus","volume":"16","author":"McVeigh","year":"1996","journal-title":"Am J Nephrol"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/01.HYP.31.1.68","article-title":"Baroreflex control of sympathetic nerve activity in essential and secondary hypertension","volume":"31","author":"Grassi","year":"1998","journal-title":"Hypertension"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB29","first-page":"114","article-title":"Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man","volume":"57","author":"Kaijser","year":"1979","journal-title":"Med Biol"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-2275(20)42668-9","article-title":"Short-term effect of nicotinic acid on plasma level and turnover of free fatty acids in sheep and man","volume":"10","author":"Nye","year":"1969","journal-title":"J Lipid Res"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/clpt.1991.104","article-title":"Tolerance to nicotinic acid flushing","volume":"50","author":"Stern","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/00365519209090131","article-title":"Effects of nicotinic acid on glucose tolerance and glucose incorporation into adipose tissue in hypertriglyceridaemia","volume":"52","author":"Wahlberg","year":"1992","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB33","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1152\/ajpendo.2000.279.1.E50","article-title":"Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women","volume":"279","author":"Wang","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-1-4615-6866-7_18","article-title":"The effects of 5-methylpyrazole-3-carboxylic acid (U-19, 425) and nicotinic acid (NA) on free fatty acids (FFAs), triglycerides (TG) and cholesterol in man","volume":"4","author":"Gunderson","year":"1969","journal-title":"Adv Exp Med Biol"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1586\/14779072.6.3.343","article-title":"Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity","volume":"6","author":"Bays","year":"2008","journal-title":"Exp Rev Cardiovasc Ther"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB36","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.amjcard.2005.01.073","article-title":"Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia","volume":"95","author":"Vega","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cpt1969104559","article-title":"The relationship between the plasma concentration of free nicotinic acid and some of its pharmacologic effects in man","volume":"10","author":"Svedmyr","year":"1969","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB38","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1113\/jphysiol.2006.112649","article-title":"Neurally mediated vasoconstriction is capable of decreasing skin blood flow during orthostasis in the heat-stressed human","volume":"575","author":"Shibasaki","year":"2006","journal-title":"J Physiol"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"Coronary Drug Project Research Group","year":"1975","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB40","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB41","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","article-title":"Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1","volume":"81","author":"Lai","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB42","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.clpt.6100345","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist","volume":"83","author":"Lai","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB44","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1172\/JCI27160","article-title":"Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid","volume":"115","author":"Pike","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB45","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0026-0495(03)00157-4","article-title":"Mechanisms of high-density lipoprotein cholesterol effects on the endothelial function in hyperlipidemia","volume":"52","author":"Lupattelli","year":"2003","journal-title":"Metabolism"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB46","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.atherosclerosis.2006.02.027","article-title":"Vasodilation in resistance arteries is related to the apolipoprotein B\/A1 ratio in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study","volume":"190","author":"Lind","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB47","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1161\/01.RES.0000225982.01988.93","article-title":"Endothelial and antithrombotic actions of HDL","volume":"98","author":"Mineo","year":"2006","journal-title":"Circ Res"},{"key":"10.1111\/j.1742-1241.2008.01934.x-BIB48","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0002-9149(01)02338-4","article-title":"Long-term safety and efficacy of a once-daily niacin\/lovastatin formulation for patients with dyslipidemia","volume":"89","author":"Kashyap","year":"2002","journal-title":"Am J Cardiol"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2008.01934.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2008.01934.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:06:07Z","timestamp":1643349967000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2008.01934.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01934.x","relation":{},"ISSN":["1368-5031","1742-1241"],"issn-type":[{"value":"1368-5031","type":"print"},{"value":"1742-1241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}